AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03780777 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Hazard Removal
Description: Removal of home barriers or hazards
Study NCT04937322 — intervention group
Intervention type: PROCEDURE
Intervention: Interventional Endoscopy procedures
Description: • All patients who have had Interventional Endoscopy procedures done which involved radio frequency ablations and stent insertion(s) for pancreatico-biliary disorders.
Study NCT02588872 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet-rich Plasma (PRP)
Study NCT02588872 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic Acid
Study NCT01552759 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Postprandial responses
Description: Subjects ingest a fixed meal, with blood draws to measure appetite hormone levels taken before and after the meal.
Study NCT01552759 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cold pressor test
Description: Subjects then undergo the Socially-Evaluated Cold Pressor Test, with blood draws to measure appetite hormone levels taken before and after the test.
Study NCT01552759 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Test meal
Description: Subjects are presented with an ad libitum buffet meal.
Study NCT04089189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMP4297
Description: IMP4297 100mg PO QD
Study NCT05680753 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Physiotherapy
Study NCT05680753 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: Physiotherapy
Study NCT00916708 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intensive/Low-Risk follow up (IA G1; IA G2)
Description: - First 2 years of FU since the end of primary treatment: clinical visit\* every 4 months; Pap tests; chest, abdomen, pelvis CT every 12 months~- Since the third to the fifth year of FU: clinical visit\* every 6 months; Pap test every 12 months~\* clinical visit with gynecological exploration
Study NCT00916708 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intensive/High-Risk follow up (≥ IA G3)
Description: - First 3 years of FU since the end of primary treatment: clinical visit\*, Ca125, trans-vaginal and abdominal ultrasound every 4 months (except in conjunction with TC); Pap smear, abdomen, pelvis CT every 12 months~- In the fourth and fifth years of FU: clinical visit\*, Ca125, trans-vaginal and abdominal ultrasound every 6 months (except in conjunction with TC) Pap smear; chest, abdomen, pelvis CT every 12 months~\* clinical visit with gynecological exploration
Study NCT00916708 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimalist/Low-Risk follow up (IA G1; IA G2)
Description: - First 5 years of FU since the end of primary treatment: clinical visit\* every 6 months.~\* clinical visit with gynecological exploration
Study NCT00916708 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimalist/High-Risk follow up (≥ IA G3)
Description: - First 2 years of FU since the end of primary treatment: clinical visit\* every 4 months; chest, abdomen, pelvis CT every 12 months~- Since the third to the fifth year of surveillance: clinical visit\* every 6 months.~\* clinical visit with gynecological exploration
Study NCT03053453 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Surgery
Description: TKA under standard of care spinal surgery.
Study NCT03053453 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Verasense Knee System device
Description: Sensor measures and localizes peak load at the medial and lateral tibiofemoral joint interfaces. Loading data is thereby captured intra-operatively through the full range of movement (ROM) using the sensor system.
Study NCT01243788 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol/Fluticasone Propionate
Description: Salmeterol/Fluticasone 50/500ug twice daily Duration:12 weeks
Study NCT03332784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-925
Description: TAK-925 Intravenous Infusion
Study NCT03332784 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TAK-925 Placebo Intravenous Infusion
Study NCT02985359 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Nutributter
Description: Daily 20g Nutributter provided to children 6 to 24 month of age
Study NCT02985359 — intervention group
Intervention type: BEHAVIORAL
Intervention: Social Behavioral Change Communication (SBCC)
Description: Social Behavioral Change Communication (SBCC) activity focused on improving infant and young child feeding (IYCF) practices and water, sanitation, and hygiene (WASH) behaviors through community groups.
Study NCT04489277 — intervention group
Intervention type: DEVICE
Intervention: Endovascular Arch Procedures
Description: Endovascular Arch Procedures (TEVAR, Branch endografts, Fenestrated endografts)
Study NCT01987492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lebrikizumab
Description: Lebrikizumab will be administered as SC injections every 4 weeks at dose and schedule described in arm description.
Study NCT01987492 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lebrikizumab
Description: Lebrikizumab will be administered as SC injections every 4 weeks at dose and schedule described in arm description.
Study NCT01987492 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to lebrikizumab will be administered as SC injections every 4 weeks as per schedule described in arm description.
Study NCT02497989 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inter-personal Communication (IPC)
Description: RAs will meet older men in their households, and : i) approach the person(s), introduce self, develop rapport and request for time to discuss briefly about VMMC; ii) strike a conversation on reasons why they or their peers have not gone to be circumcised as well as reasons that would make them get circumcised, jotting down responses to guide the discussion; iii) using the 'VMMC Demand Creation Toolkit', discuss each reported barrier/facilitator carefully and completely, always ensuring the person(s) is/are engaged in the discussion (the goal is to pass correct and complete information in a relaxed and conversational manner); iv) revisiting each stated barrier/barrier and exploring what they now think about them after the discussion, and address any new or lingering concerns.
Study NCT02497989 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dedicated Service Outlets (DSO)
Description: RAs shall visit every household with eligible men to inform them about the availability of DSO sites in their neighborhoods. After describing the characteristics of DSO sites, the RA will share - both verbally and through a flyer, information on where to find DSO sites in the respective Location. RAs will respond to questions using 'All You Need to Know About VMMC' booklet, the same way current recruiters do. They will also inform potential participants that all other VMMC sites continue to serve all men regardless of age (i.e., including older men) while DSO sites will only serve men aged ≥25 years.
Study NCT02933086 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specific exercises for lumbar stabilization
Description: The Group 1 (G1) will perform therapy with specific exercises for lumbar stabilization whith the Swiss ball as a therapeutic resource, including warming; stretching of hamstrings, paraspinals, trapezes; phasic perineal exercise; tonic perineal exercise; pelvic lumbar synergism; trunk mobility; mobility of the shoulder girdle; balance; and slow pelvic balance.
Study NCT02933086 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional therapy
Description: The Group 2 (G2) will perform conventional therapy including stretching of lower limbs and trunk, with passive stretching of hamstrings; gluteus maximus; piriform; paraspinals; lumbar square; latissimus dorsi; scalene; trapezius.
Study NCT01328353 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: telehealth plus aprn triage
Description: aprn using either telephone or telephone plus video conferencing will provide triage for CCHCN
Study NCT01005797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat (LBH589), Sorafenib
Description: Starting dose of sorafenib: 400 mg bid on Day 1-28 of each 28-day cycle; of LBH589: 15 mg on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26 of each 28-day cycle. Administered simultaneously.
Study NCT04438720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended Release Nifedipine Tablets 30 mg
Description: The subjects randomly received single oral administration of extended release nifedipine tablets 30 mg.
Study NCT03548350 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HealthyKidz physical activity programme
Description: A 24 week physical activity intervention to promote fitness and wellbeing in primary schools
Study NCT03438942 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic acid and iron supplementation
Description: Individuals with low level of blood folic acid and iron- will receive folic acid and iron supplementation daily, for 3 months
Study NCT03438942 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Individuals with proper level of blood folic acid and iron- will not receive folic acid and iron supplementation daily, for 3 months
Study NCT02942121 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LifeScience Technologies application
Description: Application for mobile devices. The app enables users to review educational videos about a surgery and recovery from a surgery from home. It also enables the user to track different metrics specific to the user's health.
Study NCT04569929 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: (DLP)-printed photo-polymerizable PMMA Nextdent mandibular implant overdenture
Description: The bite registration records with their corresponding master casts were digitalized using an extra oral desktop 3D scanner (3shape D850) and then stored as standard triangulation language (STL) files (Figure 1). The STL files were then imported to Dental system PREMIUM3 design software (3Shape Dental System 2018) for model analysis, surveying and blocking out, designing full permanent denture bases, and for virtual teeth set-up following the recorded inter-arch space
Study NCT04569929 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: (DLP)-printed photo-polymerizable PMMA Nextdent mandibular implant overdenture
Description: The bite registration records with their corresponding master casts were digitalized using an extra oral desktop 3D scanner (3shape D850) and then stored as standard triangulation language (STL) files (Figure 1). The STL files were then imported to Dental system PREMIUM3 design software (3Shape Dental System 2018) for model analysis, surveying and blocking out, designing full permanent denture bases, and for virtual teeth set-up following the recorded inter-arch space
Study NCT05201443 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diode laser
Description: Diode Laser is applied to one group as an adjunctive therapy.
Study NCT05201443 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Titanium curettes
Description: Non-surgical treatment with titanium curettes were administrated to both groups.
Study NCT05201443 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Titanium curettes
Description: Non-surgical treatment with titanium curettes were administrated to both groups.
Study NCT02849704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Creon36™
Description: Creon36™ delayed-release capsules, a pancreatic enzyme preparation, is an FDA approved medication. Subjects with chronic pancreatitis (CP) will take Creon36™ for nine days, at a daily dose of 72,000 lipase units per meal (two capsules) and 36,000 units per snack (one capsule), with each capsule containing 36,000 lipase units. Subjects will take Creon36™ for three days prior to Visit 2, the day of Visit 2 and then for five days after the visit until they have completed stool collections.
Study NCT03016468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parenteral Remodulin (treprostinil) injection
Description: Remodulin will be provided in vial strengths of 1, 2.5, 5, and 10 mg/mL. Subjects will be admitted to the hospital and IV Remodulin will be initiated within 12 hours after the last dose of selexipag. Subjects will remain under observation in the inpatient setting for at least the first 72 hours of Remodulin administration. Subjects will be transitioned to an equivalent dose of SC Remodulin at discharge.
Study NCT03016468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Treprostinil
Description: Oral treprostinil will be provided as 0.125-, 0.25-, 1-, or 2.5-mg extended-release tablets. Oral treprostinil will be dosed three times daily with food.
Study NCT00734656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dutasteride + ethanol
Description: 4 mg dutasteride administered 2-4 days prior to ingestion of 0.8 mg/kg ethanol divided between three drinks consumed over 36 minutes
Study NCT00734656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo medication + ethanol
Description: placebo medication administered 2-4 days prior to ingestion of 0.8 gr/kg ethanol divided between three drinks consumed over 36 minutes
Study NCT00734656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dutasteride + placebo alcohol
Description: 4 mg dutasteride administered 2-4 days prior to ingestion of three drinks each containing 1 cc ethanol consumed over 36 minutes
Study NCT00734656 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo medication + placebo alcohol
Description: placebo medication administered 2-4 days prior to ingestion of three drinks each containing 1 cc ethanol consumed over 36 minutes
Study NCT03127761 — intervention group
Intervention type: OTHER
Intervention: Allogeneic Hematopoietic Stem Cell Transplant
Description: This observational study will compare outcomes of prospectively enrolled HCT recipients with outcomes of a cohort of matched autoHCT controls.
Study NCT01453790 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent-Specific Depression Education and Motivation
Description: Parent-specific written and verbal depression messages garnered from previous research were consolidated into a pamphlet and script, respectively. These are dispensed after randomization in the pediatric office. At two days, mothers in the experimental group receive a motivational telephone call.
Study NCT01453790 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General Depression Education-Motivation
Description: General depression education messages were compiled and are delivered verbally (scripted) and written (JAMA Depression Patient Page) after randomization in the pediatric office. At 2 days, mothers in the comparison group receive an attention control telephone call.
Study NCT01911793 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stoma Tube
Description: Stoma tube will be inserted into stoma at the time of surgery for patients assigned to Stoma Tube group.
Study NCT03664921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omnitram Oral Tablet
Description: Administered three times daily for 28 consecutive days.
Study NCT03664921 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Administered three times daily for 28 consecutive days.
Study NCT02707172 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: handwashing with soap
Description: handwashing with soap by a standardized 6-step handwashing technique
Study NCT02707172 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: handwashing with soap
Description: handwashing with soap by a standardized 6-step handwashing technique
Study NCT02707172 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: handwashing with water
Description: handwashing with water by a standardized 6-step handwashing technique
Study NCT02707172 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: handwashing with water
Description: handwashing with water by a standardized 6-step handwashing technique
Study NCT04438720 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Extended Release Nifedipine Tablets 30 mg (Adalat® GITS)
Description: The subjects randomly received single oral administration of extended release nifedipine tablets 30 mg.
Study NCT01810523 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative
Description: Narrative form as described above.
Study NCT01810523 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Blank piece of paper
Study NCT04871399 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Right hemicolectomy (Non-CME)
Description: Transecting the Ileocolic Vein and Artery close to the Superior Mesenteric Vessels without clearing the superior mesenteric vein (SMV) from the adipose tissue. Transecting the Right Colic Vein and Artery and superior right colic vein (when present) peripherally. Transecting the Right branches of the Middle Colic Vein (MCV) and the Middle Colic Artery (MCA) peripherally, without clearing the main trunk of the MCV and the MCA. The Right Gastroepiploic Vein and artery are never transacted.
Study NCT04871399 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Right hemicolectomy with CME+CVL
Description: Separation of the visceral fascia from the parietal fascia by sharp dissection leaving intact mesocolon coverage. Transecting the supplying vessels at their origin from the main vessels, particularly:~* The Ileocolic Vessels, The Right Colic Vessels,The superior right colic vein (when present), The Right branches of the Middle Colic Vein and of the Middle Colic Artery~* The MCV and MCA at their origin in case of cancer of the hepatic flexure or of the proximal third of the transverse colon, as well as The Right Gastroepiploic Vessels at their origin from the gastrocolic trunk of Henle (GCTH) and the gastroduodenal artery.~The SMV should be cleared from all adipose tissue all along its anterior surface until its intrapancreatic entrance.
Study NCT02698709 — intervention group
Intervention type: OTHER
Intervention: Analysis of anterior and posterior corneal surfaces
Description: Corneal data obtained from a Scheimpflug-based topographer were converted to astigmatic vectors in accordance to the method proposed by Thibos
Study NCT01716611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolvaptan
Description: 15 - 60 mg/day for 28 days
Study NCT01716611 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT03917979 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual GIM
Description: Participants are provided with a series of 10 individual GIM sessions, scheduled once every two weeks. Frequency may change if clinically indicated. Individual GIM sessions begin with a discussion of important issues related to the client's life and symptoms, forming a focus for the session. Then, the therapist provides suggestions to help the client become highly relaxed and focused in preparation for the music-listening portion of the session. The therapist plays specially-selected music from the Western classical tradition to match the client and the focus for the session, and engages in verbal dialogue with the client to help them explore their own internal imagery while listening to the music. After the music ends, the therapist and client engage in discussion about their imagery in metaphoric connection to their therapeutic process. This may include arts-based approaches to process the session. Sessions last approximately 90-120 minutes.
Study NCT03917979 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Waitlist Control
Description: Participants complete an initial wait list period of 26 weeks, equivalent to the treatment and 6-week follow-up period for the experimental arm. They are then provided with four Group GIM sessions scheduled once per week. Group GIM sessions start with a group discussion about events or feelings from the week and issues related to depression and wellbeing. Then the therapist provides suggests to help the clients relax and focus in preparation for the music-listening period. Group members will explore a theme or issue related to therapy while focusing on whatever comes to them as the music is played. After the music, there will be a time to work with the imagery experienced during the music. This may be in the form of discussion or other art forms. The session ends with a discussion about gains and insights from the music and imagery. Sessions last 90-120 minutes.
Study NCT01754766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-229666
Description: One drop of AGN-229666 into each eye on Day 1 and Day 15.
Study NCT01754766 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: vehicle of AGN-229666
Description: One drop of vehicle of AGN-229666 into each eye on Day 1 and Day 15.
Study NCT04248478 — intervention group
Intervention type: OTHER
Intervention: Eating Behaviours
Description: Patients' eating behaviour will be questioned with Three Factor Eating Questionnaire. The 18-item Three-Factor Eating Questionnaire is a scale that measures three domains of eating behavior: cognitive restraint , uncontrolled eating and emotional eating.
Study NCT04248478 — intervention group
Intervention type: OTHER
Intervention: Health Status
Description: The effect of fibromyalgia on the daily life of the patients will be questioned with Fibromyalgia Impact Questionnaire (FIQ). The FIQ was developed from information gathered from patient reports, functional status instruments, and clinical observations. This instrument measures physical functioning, work status (missed days of work and job difficulty), depression, anxiety, morning tiredness, pain, stiffness, fatigue, and well-being over the past week.
Study NCT01722279 — intervention group
Intervention type: PROCEDURE
Intervention: Bariatric surgery